We are live on
!
Find out more
IMUC
ImmunoCellular Therapeutics, Ltd.
IMUC
IMUC
Delisted
IMUC was delisted on the 16th of October, 2018.
34 hedge funds and large institutions have $3.35M invested in ImmunoCellular Therapeutics, Ltd. in 2016 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
300% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 2
21% more funds holding
Funds holding: 28 → 34 (+6)
2% less capital invested
Capital invested by funds: $3.41M → $3.35M (-$55.9K)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
Holders
34
Holders Change
+6
Holders Change %
+21.43%
% of All Funds
0.91%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
5
Reduced
6
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
B
Bailard
Foster City,
California
|
+$633K |
| 2 |
CI
Cowen Inc
New York
|
+$63.5K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$36.3K |
| 4 |
Renaissance Technologies
New York
|
+$19.6K |
| 5 |
GC
Guggenheim Capital
Chicago,
Illinois
|
+$5.25K |
Top Sellers
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$9.16K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
-$5.16K |
| 3 |
GF
Gerstein Fisher
New York
|
-$5K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$4.56K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.79K |
